Compare MFP & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MFP | TRVI |
|---|---|---|
| Founded | 2025 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2025 | 2019 |
| Metric | MFP | TRVI |
|---|---|---|
| Price | $44.85 | $15.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $46.67 | $28.18 |
| AVG Volume (30 Days) | 409.1K | ★ 1.8M |
| Earning Date | 11-17-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.60 | N/A |
| Revenue Next Year | $6.07 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.51 | $9.82 |
| 52 Week High | $52.58 | $20.22 |
| Indicator | MFP | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 60.86 | 62.87 |
| Support Level | $39.58 | $13.08 |
| Resistance Level | $46.15 | $15.96 |
| Average True Range (ATR) | 2.04 | 0.72 |
| MACD | 0.36 | 0.29 |
| Stochastic Oscillator | 97.62 | 98.80 |
Midera Food Processing Inc provides food processing equipment and automation solutions for industrial protein, bakery, and snack producers, delivering total line solutions from preparation and thermal processing through packaging. The company operates through a portfolio of brands and serves food processors globally. It serves various international food processing companies and producers of protein products, such as bacon, charcuterie, sausage and hot dogs, egg bites, poultry, alternative protein, lunch meat and pet food, and producers of bakery products, such as bread and buns, artisan bread, cakes and muffins, etc. The company generates revenue from the design, manufacturing and installation of food processing equipment and technology solutions and aftermarket parts and service.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.